Everything below concerns HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
January 23: Law granting women the right to vote in elections for commercial courts. April 1: Law on mutual aid societies: these can notably be founded by women, and if the woman is married, she does not need her husband's involvement to do so. 1900
== Gottron's sign == Gottron's sign is erythematous or violaceous macules or plaques overlying the elbows and/or knees, and it is considered a less specific finding for DM. The macules or plaques follow the same symmetric distribution pattern as Gottron's papules but do not appear in the interphalangeal spaces. This is a contrasting dermatologic distribution pattern to what is observed in patients with systemic lupus erythematosus.
== Regulation and oversight == Some governmental bodies, including the European Union as well as NIOSH and the United States Environmental Protection Agency (EPA), regulate concentrations of PAHs in air, water, and soil. The European Commission has restricted concentrations of 8 carcinogenic PAHs in consumer products that contact the skin or mouth. Priority polycyclic aromatic hydrocarbons identified by the US EPA, the US Agency for Toxic Substances and Disease Registry (ATSDR), and the European Food Safety Authority (EFSA) due to their carcinogenicity or genotoxicity and/or ability to be monitored are the following:
=== Amber codon suppression === The possibility of reassigning codons was realized by Normanly et al. in 1990, when a viable mutant strain of E. coli read through the UAG ("amber") stop codon. This was possible thanks to the rarity of this codon and the fact that release factor 1 alone makes the amber codon terminate translation. Later, in the Schultz lab, the tRNATyr/tyrosyl-tRNA synthetase (TyrRS) from Methanococcus jannaschii, an archaebacterium, was used to introduce a tyrosine instead of STOP, the default value of the amber codon. This was possible because of the differences between the endogenous bacterial syntheses and the orthologous archaeal synthase, which do not recognize each other. Subsequently, the group evolved the orthologonal tRNA/synthase pair to utilize the non-standard amino acid O-methyltyrosine. This was followed by the larger naphthylalanine and the photocrosslinking benzoylphenylalanine, which proved the potential utility of the system. The amber codon is the least used codon in Escherichia coli, but hijacking it results in a substantial loss of fitness. One study, in fact, found that there were at least 83 peptides majorly affected by the readthrough. Additionally, the labelling was incomplete. As a consequence, several strains have been made to reduce the fitness cost, including the removal of all amber codons from the genome. In most E. coli K-12 strains (viz. Escherichia coli (molecular biology) for strain pedigrees) there are 314 UAG stop codons. Consequently, a gargantuan amount of work has gone into the replacement of these.
Sources: en.wikipedia.org
Canada is religiously diverse, encompassing a wide range of beliefs and customs. The Constitution of Canada refers to God; however, Canada has no official church and the government is officially committed to religious pluralism. Freedom of religion in Canada is a constitutionally protected right. Rates of religious adherence have steadily decreased since the 1970s. With Christianity in decline after having once been central and integral to Canadian culture and daily life, Canada has become a post-Christian, secular state. Although the majority of Canadians consider religion to be unimportant in their daily lives, they still believe in God. The practice of religion is generally considered a private matter. According to the 2021 census, Christianity is the largest religion in Canada, with Roman Catholics representing 29.9 percent of the population having the most adherents. Christians overall representing 53.3 percent of the population, are followed by people reporting irreligion or having no religion at 34.6 percent. Other faiths include Islam (4.9%), Hinduism (2.3%), Sikhism (2.1%), Buddhism (1.0%), Judaism (0.9%), and Indigenous spirituality (0.2%). Canada has the second-largest national Sikh population, behind India.
Alcohol: Most drinking alcohol is ethanol, CH3CH2OH. Drinking alcohol creates intoxication, relaxation and lowered inhibitions. It is produced by the fermentation of sugars by yeasts to create wine, beer, and distilled liquor (e.g., vodka, rum, gin, etc.). In most areas of the world, it is legal for those over a certain age (18 in most countries). It is an IARC Group 1 carcinogen and a teratogen. Alcohol withdrawal can be life-threatening. Amphetamines: Used recreationally to provide alertness and a sense of energy. Prescribed for ADHD, narcolepsy, depression, and weight loss. A potent central nervous system stimulant, in the 1940s and 50s methamphetamine was used by Axis and Allied troops in World War II, and, later on, other armies, and by Japanese factory workers. It increases muscle strength and fatigue resistance and improves reaction time. Methamphetamine use can be neurotoxic, which means it damages dopamine neurons. As a result of this brain damage, chronic use can lead to post acute withdrawal syndrome. Caffeine: Often found in coffee, black tea, energy drinks, some soft drinks (e.g., Coca-Cola, Pepsi, and Mountain Dew, among others), and chocolate. It is the world's most widely consumed psychoactive drug, but has only mild dependence liability for long-term users. Cannabis: Its common forms include marijuana and hashish, which are smoked, vaporized or eaten. It contains at least 85 cannabinoids. The primary psychoactive component is THC, which mimics the neurotransmitter anandamide, named after the Sanskrit word ananda meaning "joy, bliss, delight".
1883. A Treatise on the Motion of Vortex Rings: An essay to which the Adams Prize was adjudged in 1882, in the University of Cambridge. London: Macmillan and Co., pp. 146. Recent reprint: ISBN 0-543-95696-2. 1888. Applications of Dynamics to Physics and Chemistry. London: Macmillan and Co., pp. 326. Recent reprint: ISBN 1-4021-8397-6. 1893. Notes on recent researches in electricity and magnetism: intended as a sequel to Professor Clerk-Maxwell's 'Treatise on Electricity and Magnetism'. Oxford University Press, pp. xvi & 578. 1991, Cornell University Monograph: ISBN 1-4297-4053-1. Thomson, Joseph John (1893). Notes on recent researches in electricity and magnetism. Oxford: Clarendon Press. Thomson, Joseph John (1900). Discharge of electricity through gases (in German). Leipzig: Johann Ambrosius Barth. Thomson, Joseph John (1904). Electricity and matter (in English). Oxford : Clarendon Press. Thomson, Joseph John (1905). Electricity and matter (in Italian). Milano: Hoepli. Thomson, Joseph John (1908). Corpuscular theory of matter (in German). Braunschweig: Vieweg und Sohn. 1921 (1895). Elements of the Mathematical Theory of Electricity And Magnetism. London: Macmillan and Co. Scan of 1895 edition. A Text book of Physics in Five Volumes, co-authored with J.H. Poynting: (1) Properties of Matter, (2) Sound, (3) Heat, (4) Light, and (5) Electricity and Magnetism. Dated 1901 and later, and with revised later editions. Dahl, Per F. (1997). Flash of the Cathode Rays: A History of J J Thomson's Electron. Bristol and Philadelphia: Institute of Physics Publishing. ISBN 0-7503-0453-7.
Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is taken by mouth or given by injection into a vein. It is recommended that it be used for as short a period as possible and at a low dose. Common side effects include abdominal pain, dizziness, swelling, headache, and a rash. Serious side effects may include heart disease, stroke, kidney problems, and stomach ulcers. Use is not recommended in the third trimester of pregnancy. It blocks cyclooxygenase-2 (COX-2) more than it blocks cyclooxygenase-1 (COX-1). It is in the oxicam family of chemicals and is closely related to piroxicam. It is available as a generic medication. In 2023, it was the 27th most commonly prescribed medication in the United States, with more than 20 million prescriptions. An intravenous version of meloxicam (Anjeso) was approved for medical use in the United States in February 2020. Meloxicam is available in combination with bupivacaine as bupivacaine/meloxicam and in combination with rizatriptan as meloxicam/rizatriptan.
10 September – As the newly discovered BA.2.86 COVID-19 variant (known unofficially as Pirola) continues to spread, Professor Rowland Kao, an infections expert from the University of Edinburgh, calls for lateral flow COVID tests to be made freely available again. 13 September – Alister Jack, the Secretary of State for Scotland, confirms the UK government will not block Scottish Government plans for a drug consumption room pilot scheme in Scotland. 19 September – The Scottish Government begins its legal challenge against Westminster over the UK government's decision to block the controversial Gender Recognition Reform (Scotland) Bill. 20 September – Elena Whitham, the Minister for Drugs and Alcohol Policy, announces plans to launch a consultation on raising the minimum price of alcohol in Scotland to 65p a unit. 21 September – Hunter Street Health Centre in the East End of Glasgow is earmarked as the site of the UK's first legal drugs consumption centre. 26 September – Data released by National Records of Scotland indicates life expectancy in Scotland has fallen for the third consecutive year, with the average age now 76.5 years for men and 80.7 years for women; the decrease from 2022 is three weeks for men and six weeks for women. 27 September – Glasgow's Integration Joint Board approves the UK's first official drugs consumption room for illegal drugs.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.